Agilent Technologies
A · Life Sciences Tools & Services
$173.07
0.5%Thermo Fisher Scientific
TMO · Life Sciences Tools & Services
$673.82
0.4%The short version
- Thermo Fisher Scientific is the larger business, with $44.6B of revenue in fiscal 2025 against $6.9B for Agilent Technologies, about 6.4 times as much.
- Agilent Technologies grew revenue faster (6.7%, against 3.9%).
- Agilent Technologies kept more of each dollar of sales as operating profit (21.3% operating margin, against 17.4% operating margin).
- Agilent Technologies turned more of its sales into free cash flow (16.6% FCF margin, against 14.1% FCF margin).
- Agilent Technologies earned a higher return on the capital invested in it (16.5%, against 9.1%).
- Investors pay more for each dollar of Thermo Fisher Scientific’s earnings: a P/E of 36.2x against 34.1x for Agilent Technologies.
| Latest fiscal year | A · FY25 | TMO · FY25 |
|---|---|---|
| Size | ||
| Market cap | $49.0B | $250.0B |
| Revenue | $6.9B | $44.6B |
| Free cash flow | $1.2B | $6.3B |
| Net income | $1.3B | $6.7B |
| Growth | ||
| Revenue growth | 6.7% | 3.9% |
| 5-year growth | 5.4% | 6.7% |
| Share count change | −2.1% | −1.3% |
| Profitability | ||
| Gross margin | 52.4% | — |
| Operating margin | 21.3% | 17.4% |
| Net margin | 18.8% | 15.1% |
| FCF margin | 16.6% | 14.1% |
| Return on capital | 16.5% | 9.1% |
| Return on equity | 20.6% | 13.0% |
| Balance sheet | ||
| Net debt | $1.6B | $29.3B |
| Net debt / EBITDA | 0.9x | 2.8x |
| Dividends and buybacks | $707M | $3.6B |
| Valuation & quality | ||
| P/E | 34.1x | 36.2x |
| Piotroski F-score | 5 | 7 |
FY16
A $4.2B
TMO $18.3B
FY17
A $4.5B
TMO $20.9B
FY18
A $4.9B
TMO $24.4B
FY19
A $5.2B
TMO $25.5B
FY20
A $5.3B
TMO $32.2B
FY21
A $6.3B
TMO $39.2B
FY22
A $6.8B
TMO $44.9B
FY23
A $6.8B
TMO $42.9B
FY24
A $6.5B
TMO $42.9B
FY25
A $6.9B
TMO $44.6B
A
TMO
FY16
A 14.6%
TMO 13.5%
FY17
A 18.1%
TMO 14.2%
FY18
A 18.4%
TMO 15.5%
FY19
A 18.2%
TMO 18.0%
FY20
A 15.9%
TMO 24.2%
FY21
A 21.3%
TMO 25.6%
FY22
A 23.6%
TMO 18.7%
FY23
A 19.8%
TMO 16.0%
FY24
A 22.9%
TMO 17.1%
FY25
A 21.3%
TMO 17.4%
A
TMO
FY16
A $654M
TMO $2.8B
FY17
A $713M
TMO $3.5B
FY18
A $910M
TMO $3.8B
FY19
A $866M
TMO $4.0B
FY20
A $802M
TMO $6.8B
FY21
A $1.3B
TMO $6.8B
FY22
A $1.0B
TMO $6.9B
FY23
A $1.5B
TMO $6.9B
FY24
A $1.4B
TMO $7.3B
FY25
A $1.2B
TMO $6.3B
A
TMO
FY16
A 14.5%
TMO 7.1%
FY17
A 17.7%
TMO 6.7%
FY18
A 10.9%
TMO 7.7%
FY19
A 19.0%
TMO —
FY20
A 12.5%
TMO —
FY21
A 19.3%
TMO 15.0%
FY22
A 19.8%
TMO 10.8%
FY23
A 17.9%
TMO 9.1%
FY24
A 16.9%
TMO 8.9%
FY25
A 16.5%
TMO 9.1%
A
TMO
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.